A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Teclistamab
Related studies linked through entity extraction aliases.
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
GMMG-HD11/DSMM XXI/64007957MMY3010
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
- Status
- RECRUITING
- Phase
- PHASE2
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
- Status
- RECRUITING
- Phase
- PHASE3
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Status
- RECRUITING
- Phase
- PHASE2
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
- Status
- RECRUITING
- Phase
- PHASE2
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Teclistamab-Daratumumab in AL Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE2
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
The Norwegian Immunotherapy in Multiple Myeloma Study
- Status
- RECRUITING
- Phase
- N/A